Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of thymosin alpha 1 for the treatment of cystic fibrosis

A cystic fibrosis, thymosin technology, used in the digestive system, organic active ingredients, non-central pain relievers, etc.

Active Publication Date: 2021-10-26
赛生药品股份国际有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A recent phase 2b clinical trial of N-acetylcysteine ​​did demonstrate an effect on lung function but not on inflammation (24)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of thymosin alpha 1 for the treatment of cystic fibrosis
  • Use of thymosin alpha 1 for the treatment of cystic fibrosis
  • Use of thymosin alpha 1 for the treatment of cystic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0048] ESEMPIO 1: Studies in cystic fibrosis implicate the role of thymosin α1 as a CFTR corrector and potentiator and anti-inflammatory agent.

[0049] Materials and methods

[0050] cell. Cell Lines and Cell Cultures - Human bronchial epithelial (HBE) cells, homozygous for the deltaF508 mutation, and its isogenic wild-type obtained from lung transplantation (CF patients) or lung resection (non-CF patients) (courtesy of Cystic Fibrosis, Italy Courtesy of LJ Galietta of the Foundation). Keep cells in air with 5% CO 2In a 37°C humidified incubator, the experiment will be completed 5 days after transplantation (21, 22). Stable lentivirus-based transduction of parental CFBE41o-cells (ΔF508 / ΔF508), originally specimend and characterized by Dr. D. Gruenert and colleagues (32) with WT-CFTR or ΔF508-CFTR, was performed by Tranzyme (Birmingham, AL). The transduced CFBE41o-cells were maintained in a medium containing 50 units / ml penicillin, 50 μg / ml streptomycin, 2 mM L-glutamine,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to thymosin α1 (Tα1) as CFTR correction agent, CFTR potentiator and anti-inflammatory drug for the treatment of cystic fibrosis.

Description

technical field [0001] The present invention relates to the use of thymosin alpha 1 (Tal) for the treatment of cystic fibrosis. More particularly, the present invention relates to the use of thymosin alpha 1 as a CFTR corrector, CFTR potentiator and anti-inflammatory agent in the treatment of cystic fibrosis. Background technique [0002] Cystic fibrosis (CF, OMIM 219700) is a life-threatening genetic disease that primarily affects the lungs and digestive system. It is a life-limiting autosomal recessive disorder that affects 70,000 people worldwide. Patients with this disorder have steadily improved over the years, largely due to earlier diagnosis, more aggressive treatment, and care provided in specialized centers (1). Researchers now have a more complete understanding of the shortcomings of CF-based molecular biology, leading to new approaches to treatment. [0003] CF is caused by mutations in the genetically encoded CF transmembrane conductance regulator (CFTR), whic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/22A61P11/00A61P1/00A61K31/702A61K31/496A61K31/7048A61K31/47
CPCA61K31/47A61K31/496A61K31/702A61K31/7048A61K38/2292A61K2300/00A61P1/00A61P1/04A61P11/00A61P29/00A61P43/00A61K45/06A61K38/22
Inventor 路易吉娜·罗马尼恩里科·加拉奇
Owner 赛生药品股份国际有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com